Segment Information

9 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Information

12. Segment Information

Segment revenue, operating (loss) income, and depreciation and amortization were as follows:

	Three Months Ended						Nine Months Ended
	June 30,						June 30,
(In thousands)	2022			2021			2022			2021
Revenue:
Medical Device	$	17,528		$	16,755		$	52,889		$	60,858
In Vitro Diagnostics		7,326			7,118			21,074			20,307
Total revenue	$	24,854		$	23,873		$	73,963		$	81,165
Operating (loss) income:
Medical Device	$	(7,308	)	$	(2,491	)	$	(16,712	)	$	5,480
In Vitro Diagnostics		3,387			3,378			10,262			10,407
Total segment operating (loss) income		(3,921	)		887			(6,450	)		15,887
Corporate		(3,222	)		(3,271	)		(9,034	)		(8,695	)
Total operating (loss) income	$	(7,143	)	$	(2,384	)	$	(15,484	)	$	7,192
Depreciation and amortization:
Medical Device	$	2,020		$	1,631		$	6,347		$	5,004
In Vitro Diagnostics		88			121			260			314
Corporate		98			92			295			292
Total depreciation and amortization	$	2,206		$	1,844		$	6,902		$	5,610

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.